Xenon Pharmaceuticals Inc.
US ˙ NasdaqGM ˙ CA98420N1050

SecurityXENE / Xenon Pharmaceuticals Inc.
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership18,940 shares
Latest Disclosed Value $ 1,101,361
D. E. Shaw & Co., Inc. ownership in XENE / Xenon Pharmaceuticals Inc.

On May 15, 2026 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 18,940 shares of Xenon Pharmaceuticals Inc. (US:XENE) valued at $1,101,361 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 30,851 shares of Xenon Pharmaceuticals Inc.. This represents a change in shares of -38.61% during the quarter. The current value of the position is $1,012,532 USD.

D. E. Shaw & Co., Inc. has a history of taking positions in derivatives of the underlying security (XENE) in the form of stock options. The firm currently holds call options representing 19,800 of underlying shares valued at $1,151,370 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

XENE / Xenon Pharmaceuticals Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F XENON PHARMACEUTICALS COM 98420N105 18,940 -11,911 -38.61 1,101 -20.33 0.0007
2026-02-17 2025-12-31 13F XENON PHARMACEUTICALS COM 98420N105 30,851 -17,604 -36.33 1,383 -28.95 0.0008
2025-11-14 2025-09-30 13F XENON PHARMACEUTICALS COM 98420N105 48,455 -93,328 -65.82 1,945 -56.16 0.0011
2025-08-14 2025-06-30 13F XENON PHARMACEUTICALS COM 98420N105 141,783 -10,405 -6.84 4,438 -13.09 0.0031
2025-05-15 2025-03-31 13F XENON PHARMACEUTICALS COM 98420N105 152,188 65,215 74.98 5,106 49.75 0.0045
2025-02-14 2024-12-31 13F XENON PHARMACEUTICALS COM 98420N105 86,973 -117,919 -57.55 3,409 -57.74 0.0025
2024-11-14 2024-09-30 13F XENON PHARMACEUTICALS COM 98420N105 204,892 43,170 26.69 8,067 27.93 0.0069
2024-08-14 2024-06-30 13F XENON PHARMACEUTICALS COM 98420N105 161,722 -36,804 -18.54 6,306 -26.22 0.0059
2024-05-15 2024-03-31 13F XENON PHARMACEUTICALS COM 98420N105 198,526 114,373 135.91 8,547 120.49 0.0073
2024-02-14 2023-12-31 13F XENON PHARMACEUTICALS COM 98420N105 84,153 43,606 107.54 3,876 179.86 0.0034
2023-11-14 2023-09-30 13F XENON PHARMACEUTICALS COM 98420N105 40,547 -58,198 -58.94 1,385 -63.56 0.0014
2023-08-14 2023-06-30 13F XENON PHARMACEUTICALS COM 98420N105 98,745 -107,927 -52.22 3,802 -48.61 0.0039
2023-05-15 2023-03-31 13F XENON PHARMACEUTICALS COM 98420N105 206,672 -153,749 -42.66 7,397 -47.96 0.0079
2023-02-14 2022-12-31 13F XENON PHARMACEUTICALS COM 98420N105 360,421 -49,142 -12.00 14,211 -3.88 0.0157
2022-11-14 2022-09-30 13F XENON PHARMACEUTICALS COM 98420N105 409,563 83,021 25.42 14,785 48.85 0.0177
2022-08-15 2022-06-30 13F XENON PHARMACEUTICALS COM 98420N105 326,542 -3,985 -1.21 9,933 -1.69 0.0116
2022-05-16 2022-03-31 13F XENON PHARMACEUTICALS COM 98420N105 330,527 -144,613 -30.44 10,104 -31.93 0.0095
2022-02-14 2021-12-31 13F XENON PHARMACEUTICALS COM 98420N105 475,140 326,261 219.15 14,843 552.44 0.0123
2021-11-15 2021-09-30 13F XENON PHARMACEUTICALS COM 98420N105 148,879 -15,192 -9.26 2,275 -25.53 0.0021
2021-08-16 2021-06-30 13F XENON PHARMACEUTICALS COM 98420N105 164,071 -10,924 -6.24 3,055 -2.49 0.0026
2021-05-17 2021-03-31 13F XENON PHARMACEUTICALS COM 98420N105 174,995 -8,745 -4.76 3,133 10.86 0.0030
2021-02-16 2020-12-31 13F XENON PHARMACEUTICALS COM 98420N105 183,740 -8,573 -4.46 2,826 32.74 0.0025
2020-11-16 2020-09-30 13F XENON PHARMACEUTICALS COM 98420N105 192,313 -17,305 -8.26 2,129 -19.02 0.0022
2020-08-14 2020-06-30 13F XENON PHARMACEUTICALS COM 98420N105 209,618 67,110 47.09 2,629 62.69 0.0031
2020-05-15 2020-03-31 13F XENON PHARMACEUTICALS COM 98420N105 142,508 95,631 204.00 1,616 162.76 0.0025
2020-02-14 2019-12-31 13F XENON PHARMACEUTICALS COM 98420N105 46,877 15,979 51.72 615 121.22 0.0007
2019-11-14 2019-09-30 13F XENON PHARMACEUTICALS COM 98420N105 30,898 132 0.43 278 -8.25 0.0003
2019-08-14 2019-06-30 13F XENON PHARMACEUTICALS COM 98420N105 30,766 -24,866 -44.70 303 -46.37 0.0004
2019-05-15 2019-03-31 13F XENON PHARMACEUTICALS COM 98420N105 55,632 -75,588 -57.60 565 -31.76 0.0007
2019-02-14 2018-12-31 13F XENON PHARMACEUTICALS COM 98420N105 131,220 131,220 828 0.0011
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F XENON PHARMACEUTICALS COM Call 19,800 1,151 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.